Newly lesioned tissue in multiple sclerosis - A role for oxidative damage?

Brain

Volumn 134, Issue 7, 2011, Pages 1877-1881

  Smith, Kenneth J ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATE; GLUTAMIC ACID; HYPOXIA INDUCIBLE FACTOR 1ALPHA; MYELOPEROXIDASE; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; SUPEROXIDE;

CELL ACTIVATION; HUMAN; IMMUNOREACTIVITY; LYMPHOCYTE; MACROPHAGE; MICROGLIA; MITOCHONDRION; MULTIPLE SCLEROSIS; NERVE FIBER; NONHUMAN; NOTE; OLIGODENDROGLIA; OXIDATIVE STRESS; OXYGEN CONCENTRATION; PRIORITY JOURNAL; T LYMPHOCYTE; WHITE MATTER;

HUMANS; MULTIPLE SCLEROSIS; OXIDATION-REDUCTION; OXIDATIVE STRESS;

EID: 79959708097     PISSN: 00068950     EISSN: 14602156     Source Type: Journal    
DOI: 10.1093/brain/awr144     Document Type: Note

References (63)

1. Aboul-Enein F, Rauschka H, Kornek B, Stadelmann C, Stefferl A, Bruck W, et al. Preferential loss of myelin-associated glycoprotein reflects hypoxia- like white matter damage in stroke and inflammatory brain diseases. J Neuropathol Exp Neurol 2003; 62: 25-33. (Pubitemid 36068890)
2. Abramov AY, Canevari L, Duchen MR. Beta-amyloid peptides induce mitochondrial dysfunction and oxidative stress in astrocytes and death of neurons through activation of NADPH oxidase. J Neurosci 2004; 24: 565-75. (Pubitemid 38112390)
3. Andrews HE, Nichols PP, Bates D, Turnbull DM. Mitochondrial dysfunction plays a key role in progressive axonal loss in Multiple Sclerosis. Med Hypotheses 2005; 64: 669-77. (Pubitemid 40203051)
4. Barnett MH, Prineas JW. Relapsing and remitting multiple sclerosis: pathology of the newly forming lesion. Ann Neurol 2004; 55: 458-68. (Pubitemid 38391962)
5. Bedard K, Krause KH. The NOX family of ROS-generating NADPH oxi-dases: physiology and pathophysiology. Physiol Rev 2007; 87: 245-313. (Pubitemid 46209993)
6. Beltran B, Quintero M, Garcia-Zaragoza E, O'Connor E, Esplugues JV, Moncada S. Inhibition of mitochondrial respiration by endogenous nitric oxide: a critical step in Fas signaling. Proc Natl Acad Sci USA 2002; 99: 8892-7. (Pubitemid 34693654)
7. Bolanos JP, Almeida A. Modulation of astroglial energy metabolism by nitric oxide. Antioxid Redox Signal 2006; 8: 955-65. (Pubitemid 44036512)
8. Bove PF, Hristova M, Wesley UV, Olson N, Lounsbury KM, van der Vliet A. Inflammatory levels of nitric oxide inhibit airway epithelial cell migration by inhibition of the kinase ERK1/2 and activation of hypoxia-inducible factor-1 alpha. J Biol Chem 2008; 283: 17919-28.
9. Brennan AM, Suh SW, Won SJ, Narasimhan P, Kauppinen TM, Lee H, et al. NADPH oxidase is the primary source of superoxide induced by NMDA receptor activation. Nat Neurosci 2009; 12: 857-63.
10. Brunori M, Forte E, Arese M, Mastronicola D, Giuffre A, Sarti P. Nitric oxide and the respiratory enzyme. Biochim Biophys Acta 2006; 1757: 1144-54. (Pubitemid 44442121)
11. Campbell GR, Mahad DJ. Mitochondria as crucial players in demyeli-nated axons: lessons from neuropathology and experimental demye-lination. Autoimmune Dis 2011; 2011: 262847.
12. Campbell GR, Ziabreva I, Reeve AK, et al. Mitochondrial DNA deletions and neurodegeneration in multiple sclerosis. Ann Neurol 2011; 69: 481-92.
13. Desai RA, Davies AL, Smith KJ. Evidence that hypoxia and energy insufficiency play a role in central inflammation. Neuropathol Appl Neurobiol 2011; 37 (Suppl. 1): 7-8.
14. Dutta R, McDonough J, Yin X, et al. Mitochondrial dysfunction as a cause of axonal degeneration in multiple sclerosis patients. Ann Neurol 2006; 59: 478-89. (Pubitemid 43358068)
15. Dutta R, Trapp BD. Pathogenesis of axonal and neuronal damage in multiple sclerosis. Neurol 2007; 68: S22-31. (Pubitemid 46848608)
16. Frohman EM, Racke MK, Raine CS. Multiple sclerosis-the plaque and its pathogenesis. N Engl J Med 2006; 354: 942-55.
17. Gay F. Bacterial toxins and Multiple Sclerosis. J Neurol Sci 2007; 262: 105-12. (Pubitemid 47390906)
18. Gay FW, Drye TJ, Dick GW, Esiri MM. The application of multifactorial cluster analysis in the staging of plaques in early multiple sclerosis. Identification and characterization of the primary demyelinating lesion. Brain 1997; 120: 1461-83.
19. Gonsette RE. Neurodegeneration in multiple sclerosis: the role of oxida-tive stress and excitotoxicity. J Neurol Sci 2008; 274: 48-53.
20. Graumann U, Reynolds R, Steck AJ, Schaeren-Wiemers N. Molecular changes in normal appearing white matter in multiple sclerosis are characteristic of neuroprotective mechanisms against hypoxic insult. Brain Pathol 2003; 13: 554-73. (Pubitemid 37420699)
21. Gray E, Thomas TL, Betmouni S, Scolding N, Love S. Elevated activity and microglial expression of myeloperoxidase in demyelinated cerebral cortex in multiple sclerosis. Brain Path 2008a; 18: 86-95.
22. Gray E, Thomas TL, Betmouni S, Scolding N, Love S. Elevated myeloper-oxidase activity in white matter in multiple sclerosis. Neurosci Lett 2008b; 444: 195-8.
23. Hagen T, Taylor CT, Lam F, Moncada S. Redistribution of intracellular oxygen in hypoxia by nitric oxide: effect on HIF1alpha. Science 2003; 302: 1975-8. (Pubitemid 37523507)
24. Haider L, Fischer M-T, Frischer J, Hoeftberger R, Botond G, Esterbauer H, et al. Oxidative damage and neurodegeneration in multiple sclerosis lesions. Brain 2011; in press.
25. Henderson AP, Barnett MH, Parratt JD, Prineas JW. Multiple sclerosis: distribution of inflammatory cells in newly forming lesions. Ann Neurol 2009; 66: 739-53.
26. Kalman B, Laitinen K, Komoly S. The involvement of mitochondria in the pathogenesis of multiple sclerosis. J Neuroimmunol 2007; 188: 1-12. (Pubitemid 47095010)
27. Karadottir R, Attwell D. Neurotransmitter receptors in the life and death of oligodendrocytes. Neuroscience 2007; 145: 1426-38. (Pubitemid 46602726)
28. Klimova T, Chandel NS. Mitochondrial complex III regulates hypoxic activation of HIF. Cell Death Differ 2008; 15: 660-6. (Pubitemid 351405069)
29. Kuhlmann T, Lingfeld G, Bitsch A, Schuchardt J, Bruck W. Acute axonal damage in multiple sclerosis is most extensive in early disease stages and decreases over time. Brain 2002; 125: 2202-12.
30. Lassmann H. The architecture of inflammatory demyelinating lesions: implications for studies on pathogenesis. Neuropathol Appl Neurobiol 2011; in press.
31. Liu JS, Zhao ML, Brosnan CF, Lee SC. Expression of inducible nitric oxide synthase and nitrotyrosine in multiple sclerosis lesions. Am J Pathol 2001; 158: 2057-66. (Pubitemid 32545191)
32. Lucchinetti C, Bruck W, Parisi J, Scheithauer B, Rodriguez M, Lassmann H. Heterogeneity of multiple sclerosis lesions: Implications for the pathogenesis of demyelination. Ann Neurol 2000; 47: 707-17. (Pubitemid 30390191)
33. Mahad DJ, Ziabreva I, Campbell G, Lax X, White K, Hanson PS, et al. Mitochondrial changes within axons in multiple sclerosis. Brain 2009; 132: 1161-74.
34. Majmundar AJ, Wong WJ, Simon MC. Hypoxia-inducible factors and the response to hypoxic stress. Mol Cell 2010; 40: 294-309.
35. Mao P, Reddy PH. Is multiple sclerosis a mitochondrial disease? Biochim Biophys Acta 2010; 1802: 66-79.
36. Marik C, Felts PA, Bauer J, Lassmann H, Smith KJ. Lesion genesis in a subset of patients with multiple sclerosis: a role for innate immunity? Brain 2007; 130: 2800-15. (Pubitemid 350033973)
37. Murphy MP. How mitochondria produce reactive oxygen species. Biochem J 2009a; 417: 1-13.
38. Murphy MP. Mitochondria-a neglected drug target. Curr Opin Investig Drugs 2009b; 10: 1022-4.
39. Nakamura T, Lipton SA. S-nitrosylation of critical protein thiols mediates protein misfolding and mitochondrial dysfunction in neurodegenerative diseases. Antioxid Redox Signal 2011; 14: 1479-92.
40. Nikic I, Merkler D, Sorbara C, Brinkoetter M, Kreutzfeldt M, Bareyre FM, et al. A reversible form of axon damage in experimental autoimmune encephalomyelitis and multiple sclerosis. Nat Med 2011; 17: 495-9.
41. Olson N, van der Vliet A. Interactions between nitric oxide and hypoxia-inducible factor signaling pathways in inflammatory disease. Nitric Oxide 2011.
42. Palmer LA, Gaston B, Johns RA. Normoxic stabilization of hypoxia-inducible factor-1 expression and activity: redox-dependent effect of nitrogen oxides. Mol Pharmacol 2000; 58: 1197-203.
43. Ponomarev ED, Shriver LP, Maresz K, Dittel BN. Microglial cell activation and proliferation precedes the onset of CNS autoimmunity. J Neurosci Res 2005; 81: 374-89. (Pubitemid 41359292)
44. Qi X, Lewin AS, Sun L, Hauswirth WW, Guy J. Mitochondrial protein nitration primes neurodegeneration in experimental autoimmune encephalomyelitis. J Biol Chem 2006; 281: 31950-62.
45. Qi X, Lewin AS, Sun L, Hauswirth WW, Guy J. Suppression of mitochon-drial oxidative stress provides long-term neuroprotection in experimental optic neuritis. Invest Ophthalmol Vis Sci 2007a; 48: 681-91. (Pubitemid 351260701)
46. Qi X, Sun L, Lewin AS, Hauswirth WW, Guy J. Long-term suppression of neurodegeneration in chronic experimental optic neuritis: antioxidant gene therapy. Invest Ophthalmol Vis Sci 2007b; 48: 5360-70. (Pubitemid 351260834)
47. Redford EJ, Kapoor R, Smith KJ. Nitric oxide donors reversibly block axonal conduction: demyelinated axons are especially susceptible. Brain 1997; 120: 2149-57. (Pubitemid 28014591)
48. Rubbo H, Trostchansky A, O'Donnell VB. Peroxynitrite-mediated lipid oxidation and nitration: mechanisms and consequences. Arch Biochem Biophys 2009; 484: 167-72.
49. Salvetti M, Giovannoni G, Aloisi F. Epstein-Barr virus and multiple sclerosis. Curr Opin Neurol 2009; 22: 201-6.
50. Saraswathy S, Rao NA. Photoreceptor mitochondrial oxidative stress in experimental autoimmune uveitis. Ophthalmic Res 2008; 40: 160-4. (Pubitemid 351562896)
51. Smith KJ, Lassmann H. The role of nitric oxide in multiple sclerosis. Lancet Neurol 2002; 1: 232-41. (Pubitemid 37159185)
52. Smith KJ, McDonald I, Miller D, Lassmann H. The pathophysiology of multiple sclerosis. In: Compston A, Confavreux C, Lassmann H, McDonald I, Miller D, Noseworthy J, et al. editors. McAlpine's multiple sclerosis. London: Churchill Livingstone; 2006. p. 601-59.
53. Stowe DF, Camara AK. Mitochondrial reactive oxygen species production in excitable cells: modulators of mitochondrial and cell function. Antioxid Redox Signal 2009; 11: 1373-414.
54. Stys PK, Lipton SA. White matter NMDA receptors: an unexpected new therapeutic target? Trends Pharmacol Sci 2007; 28: 561-6. (Pubitemid 350030933)
55. van Horssen J, Witte ME, Schreibelt G, de Vries HE. Radical changes in multiple sclerosis pathogenesis. Biochim Biophys Acta 2011; 1812: 141-50.
56. Weiner HL. Multiple sclerosis is an inflammatory T-cell-mediated autoimmune disease. Arch Neurol 2004; 61: 1613-5. (Pubitemid 39350279)
57. Werner P, Pitt D, Raine CS. Multiple sclerosis: altered glutamate homeo-stasis in lesions correlates with oligodendrocyte and axonal damage. Ann Neurol 2001; 50: 169-80. (Pubitemid 32738141)
58. Witte ME, Bo L, Rodenburg RJ, Belien JA, Musters R, Hazes T, et al. Enhanced number and activity of mitochondria in multiple sclerosis lesions. J Pathol 2009; 219: 193-204.
59. Witte ME, Geurts JJ, de Vries HE, van der Valk P, van Horssen J. Mitochondrial dysfunction: a potential link between neuroinflamma-tion and neurodegeneration? Mitochondrion 2010; 10: 411-8.
60. Yakes FM, Van Houten B. Mitochondrial DNA damage is more extensive and persists longer than nuclear DNA damage in human cells following oxidative stress. Proc Natl Acad Sci USA 1997; 94: 514-9. (Pubitemid 27053665)
61. Zambonin JL, Zhao C, Ohno N, Campbell GR, Engeham S, Ziabreva I, et al. Increased mitochondrial content in remyelinated axons: implications for multiple sclerosis. Brain 2011; in press.
62. Zeis T, Graumann U, Reynolds R, Schaeren-Wiemers N. Normal-appearing white matter in multiple sclerosis is in a subtle balance between inflammation and neuroprotection. Brain 2008; 131: 288-303.
63. Zeis T, Probst A, Steck AJ, Stadelmann C, Bruck W, Schaeren-Wiemers N. Molecular changes in white matter adjacent to an active demyelinating lesion in early multiple sclerosis. Brain Pathol 2009; 19: 459-66.